Aspirin for prevention of preeclampsia and fetal growth restriction

Prenatal Diagnosis - Tập 40 Số 5 - Trang 519-527 - 2020
Lola Loussert1, Fabien Vidal1, Olivier Parant2,1, Safouane M. Hamdi3, Christophe Vayssière2,1, Paul Guerby4,1
1Service Gynécologie [CHU Toulouse] (Hôpital Paule de Viguier, 31300 Toulouse - France)
2Equipe SPHERE (CERPOP) (37 allées J. Guesde 31000 Toulouse - France)
3Institut Fédératif de Biologie (IFB) (Hôpital Purpan, 330, avenue de Grande-Bretagne - TSA 40031 - 31059 Toulouse cedex 9 - France)
4Equipe 7 Inserm U1048 (France)

Tóm tắt

AbstractFor the past decades, growing attention has been given to aspirin use during pregnancy. It favors placentation by its proangiogenic, antithrombotic, and anti‐inflammatory effects. Therefore, low doses of aspirin are prescribed in the prevention of placenta‐mediated complications, mainly preeclampsia and fetal growth restriction. However, questions regarding its clinical application are still debated. Aspirin is effective in preventing preeclampsia in a high‐risk population. Most guidelines recommend that risk stratification should rely on medical history. Nevertheless, screening performances dramatically improve if biochemical and biophysical markers are included. Concerning the appropriate timing and dose, latest studies suggest aspirin should be started before 16 weeks of pregnancy and at a daily dose of 100 mg or more. Further studies are needed to improve the identification of patients likely to benefit from prophylactic aspirin. Besides, the role of aspirin in the prevention of fetal growth restriction is still questioned.

Từ khóa


Tài liệu tham khảo

10.1007/s11906-014-0454-8

10.1097/01.AOG.0000437382.03963.88

10.1161/CIRCRESAHA.118.313276

10.1155/2014/297397

10.1097/AOG.0000000000003070

10.1016/0002-9378(95)91325-4

10.1016/j.ajog.2017.12.004

10.1016/j.siny.2017.11.004

10.1007/s00428-017-2239-3

10.1016/S0140-6736(85)92207-X

10.1016/j.ajog.2017.12.238

10.1093/biolre/ioy049

10.1038/s41581-019-0119-6

10.1016/S0002-9440(10)62567-9

10.1210/jc.2002-021888

Huang Y, 2008, Human trophoblasts recruited T lymphocytes and monocytes into decidua by secretion of chemokine CXCL16 and interaction with CXCR6 in the first‐trimester pregnancy, J Immunol Baltim Md 1950, 180, 2367

LecarpentierE FournierT GuibourdencheJ TsatsarisV.[Pathophysiology of preeclampsia]. Presse Medicale Paris Fr 1983.2016;45(7–8 Pt 1):631‐637.

10.1016/j.ajpath.2016.08.010

10.1111/bph.14466

10.1016/j.semnephrol.2017.05.011

10.1016/j.gyobfe.2015.09.011

Lecarpentier É, 2016, Placental growth factor (PlGF) and sFlt‐1 during pregnancy: physiology, assay and interest in preeclampsia, Ann Biol Clin (Paris), 74, 259

10.3109/00016349.2010.505639

10.1210/me.2006-0522

Jones JI, 1995, Insulin‐like growth factors and their binding proteins: biological actions, Endocr Rev, 16, 3

10.1016/j.ajog.2004.06.052

10.1002/pd.4397

10.3390/ijms19051496

10.1016/j.placenta.2017.06.007

10.1016/j.redox.2019.101126

10.1111/bcp.12301

10.3390/ijms16034600

10.1016/j.freeradbiomed.2019.07.015

10.1016/j.humpath.2010.11.018

10.3389/fphys.2016.00098

10.1038/s41598-017-06178-z

10.1016/S0049-3848(03)00379-7

10.1016/j.ejphar.2015.08.049

10.2174/1381612043453144

Morris T, 2009, Effects of low‐dose aspirin on acute inflammatory responses in humans, J Immunol Baltim Md 1950, 183, 2089

10.1007/BF01972693

10.1055/s-2007-999562

10.1016/j.placenta.2015.01.004

Goh J, 2001, Lipoxin A4 and aspirin‐triggered 15‐epi‐lipoxin A4 antagonize TNF‐α‐stimulated neutrophil‐enterocyte interactions in vitro and attenuate TNF‐α‐induced chemokine release and colonocyte apoptosis in human intestinal mucosa ex vivo, J Immunol Baltim Md 1950, 167, 2772

Ariel A, 2003, Aspirin‐triggered lipoxin A4 and B4 analogs block extracellular signal‐regulated kinase‐dependent TNF‐α secretion from human T cells, J Immunol Baltim Md 1950, 170, 6266

10.1152/ajpcell.00045.2005

10.1097/01.ASN.0000032417.73640.72

10.1038/s41371-018-0113-7

10.1002/art.38934

10.1016/j.plefa.2012.08.003

10.1530/REP-11-0021

10.1126/science.8052854

10.1016/j.freeradbiomed.2017.01.010

Doridot L, 2013, Preeclampsia‐like symptoms induced in mice by fetoplacental expression of STOX1 are reversed by aspirin treatment, Hypertens Dallas Tex 1979, 61, 662

10.1038/s41420-019-0170-x

10.1097/AOG.0b013e3181e9322a

10.1002/ijgo.12741

10.1016/j.ajog.2016.09.076

10.1016/S1701-2163(16)34346-8

10.1016/j.ajog.2019.04.027

10.1016/j.ajog.2017.11.561

10.1016/j.ajog.2019.08.047

National Collaborating Centre for Women's and Children's Health (UK), 2010, Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy [Internet]

10.1002/uog.19039

10.1111/1471-0528.15180

10.1159/000341264

10.1002/uog.17399

10.1056/NEJMoa1704559

10.1016/j.ajog.2019.02.034

10.1056/NEJMc1713798

10.1016/j.ajog.2019.05.044

10.1080/14767050902866804

10.1016/j.ajog.2017.11.577

10.1515/jpm-2017-0184

10.1136/bmj.l5119

10.1093/eurheartj/ehy813

10.7326/M13-2844

10.1542/peds.111.1.e77

10.1016/j.ajog.2004.10.598

10.1055/s-2005-864116

10.1097/AOG.0000000000001301

10.1016/S0140-6736(76)93025-7

McLaughlin K, 2015, Current theories on the prevention of severe preeclampsia with low‐molecular weight heparin, Hypertens Dallas Tex 1979, 66, 1098

10.1016/j.placenta.2014.12.008

10.1002/uog.15789

10.1097/AOG.0000000000001673

10.1016/j.ajog.2017.01.014

10.1161/HYPERTENSIONAHA.115.06357

10.1161/01.str.0000442009.06663.48

Thông tin
Thông tin xuất bản

Prenatal Diagnosis

Tập 40 Số 5

519-527

Thông tin tác giả